7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrochloride (1:1)

The main ingredient of this product is rufloxacin hydrochloride.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the elimination of theophylline in the liver, a prolonged elimination half-life (t1/2beta;), an increase in blood concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., and should be avoided. If it cannot be avoided, theophylline blood concentration should be measured and the dose adjusted. 3. When cyclosporine is used in combination with this product, its blood concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. When this product is used in combination with the anticoagulant warfarin, it can enhance the latter's anticoagulant effect. When used in combination, the patient's prothrombin time should be closely monitored and the dose adjusted. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (t1/2beta;), and may produce central nervous system toxicity. When used in combination, the patient's blood caffeine concentration should be closely monitored and the dose adjusted. 7. Antacids containing aluminum and magnesium can reduce the oral absorption of this product and should not be used in combination. 8. Avoid using it in combination with non-steroidal anti-inflammatory drugs.

The main ingredient of this product is rufloxacin hydrochloride.

1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., and should be avoided. If it cannot be avoided, theophylline blood drug concentration should be measured and the dose adjusted. 3 When cyclosporine is used in combination with this product, its blood drug concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When this product is used in combination with the anticoagulant warfarin, it can enhance the latter's anticoagulant effect. When used in combination, the patient's prothrombin time should be closely monitored and the dose adjusted. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, which leads to a decrease in caffeine elimination, a prolongation of the blood elimination half-life (t1/2beta;), and may produce central nervous system toxicity. When used together, the patient's blood caffeine concentration should be closely monitored and the dosage adjusted. 7. Antacids containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together.